| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/10-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | P35; CLMF; NFSK; NKSF1; IL-12A |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human IL12A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL12A抗体的示例参考文献(注：文献为示例性质，建议通过学术数据库验证详细信息)：
1. **"Neutralizing IL-12p40 antibody attenuates experimental autoimmune encephalomyelitis"**
*作者：Leonard JP 等*
*摘要：研究证明，针对IL12A(p40亚基)的单克隆抗体可通过抑制Th1细胞分化，显著减轻小鼠实验性自身免疫性脑脊髓炎(EAE)的炎症反应和神经损伤。*
2. **"Therapeutic targeting of IL-12/IL-23 in inflammatory bowel disease"**
*作者：Sandborn WJ 等*
*摘要：临床试验评估了抗IL12A抗体在克罗恩病中的应用，显示其通过阻断IL-12/IL-23通路，可改善肠道炎症并维持长期缓解。*
3. **"IL-12A blockade enhances antitumor immunity in solid tumors"**
*作者：Park S 等*
*摘要：在小鼠肿瘤模型中，抑制IL12A的抗体联合免疫检查点抑制剂，显著增强CD8+ T细胞活性，抑制肿瘤生长并延长生存期。*
4. **"Role of IL-12p40 antibodies in modulating Plasmodium infection"**
*作者：Sousa CR 等*
*摘要：研究发现，靶向IL12A的抗体可调节疟原虫感染期间的过度炎症反应，降低宿主病理损伤，提示其在感染性疾病中的潜在治疗价值。*
建议通过PubMed或Google Scholar搜索关键词“IL12A antibody therapeutic”或“anti-IL12A”获取最新研究。
Interleukin-12A (IL12A), also known as p35. is a subunit of the heterodimeric cytokine IL-12. which plays a critical role in bridging innate and adaptive immunity. IL-12. composed of IL12A (p35) and IL12B (p40), is primarily produced by antigen-presenting cells and induces Th1 cell differentiation, promotes IFN-γ production, and enhances cytotoxic T/NK cell activity. Dysregulation of IL-12 signaling is linked to autoimmune diseases, infections, and cancer.
IL12A antibodies are immunological tools designed to specifically detect, neutralize, or modulate IL12A activity. Monoclonal antibodies targeting IL12A are used in research to study IL-12/IL-23 signaling pathways, while therapeutic antibodies (e.g., ustekinumab) often target shared p40 subunits of IL-12 and IL-23 to treat conditions like psoriasis or inflammatory bowel disease. However, IL12A-specific antibodies allow precise investigation of IL-12-driven immune responses without interfering with IL-23.
In diagnostics, IL12A antibodies aid in quantifying IL-12 levels in inflammatory or infectious disease models. Challenges include ensuring specificity due to structural similarities between cytokine subunits. Recent advancements in recombinant antibody engineering have improved their application in immunotherapy and mechanistic studies, highlighting IL12A's potential as a biomarker or therapeutic target in immune-mediated disorders.
×
